Nippon Kayaku, Shionogi Release Cetrotide, Premature Ovulation Inhibitor, in Japan.Tokyo, Japan, Sept 21, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Shionogi and Nippon Kayaku announced on September 21 the launch in Japan of Cetrotide - cetrorelix acetate, for prevention of premature ovulation ovulation /ovu·la·tion/ (ov?u-la´shun) the discharge of a secondary oocyte from a graafian follicle.ov´ulatory o·vu·la·tion n. The discharge of an ovum from the ovary. during controlled ovarian stimulation ovarian stimulation Reproduction medicine The use of drugs to stimulate the ovaries to develop follicles - 0.25mg and 3mg for injection. Canadian biopharmaceutical company AEterna Zentaris, through German subsidiary Zentaris GmbH, is the worldwide licensor of development rights for Cetrotide, which is approved for prevention of premature ovulation in 93 countries, including countries in Europe and the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . The drug was approved for manufacturing and marketing in Japan on April 20, 2006. Nippon Kayaku Co., Ltd. will import from Zentaris and manufacture Cetrotide and Shionogi will market it. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion